| Gene symbol | MAGEA1 | Synonyms | CT1.1, MAGE1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | MAGE family member A1 | ||||
| GTO ID | GTC0536 |
| Trial ID | NCT04639245 |
| Disease | Breast Cancer | Triple-Receptor Negative Breast Cancer | Lung Non-Small Cell Carcinoma | Lung Cancer | Urothelial Carcinoma |
| Altered gene | MAGE-A1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | MAGE-A1 TCR-T cells |
| Co-treatment | Atezolizumab |
| HLA | HLA-A*02:01 |
| Phase | Phase1|Phase2 |
| Recruitment status | Terminated |
| Title | ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer |
| Year | 2020 |
| Country | United States |
| Company sponsor | Fred Hutchinson Cancer Center |
| Other ID(s) | RG1007463|NCI-2020-06602|10420 |
| Cohort 1 | |||||||||||||||
|
|||||||||||||||